A pilot study: Use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures

Journal of Rheumatology

Volumn 26, Issue 2, 1999, Pages 352-360

  Adams, Elizabeth M ^a   Pucino, Frank ^a   Yarboro, Cheryl ^a   Hicks, Jeanne E ^a   Thornton, Bonnie ^a   McGarvey, Charles ^a   Sonies, Barbara C ^a   Bartlett, Marissa L ^a   Villalba, M Lourdes ^a   Fleisher, Thomas ^a   Plotz, Paul H ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Fludarabine; Lymphocyte; MRI; Myositis; Outcome measures

Indexed keywords

ANTIINFLAMMATORY AGENT; FLUDARABINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; MUSCLE ENZYME; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME ASSAY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; MALE; MUSCLE STRENGTH; OUTCOMES RESEARCH; POLYMYOSITIS; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT FAILURE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DERMATOMYOSITIS; EDEMA; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC TESTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PILOT PROJECTS; POLYMYOSITIS; PREDNISONE; TREATMENT OUTCOME; VIDARABINE;

EID: 0032932507     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Adams EM, Plotz PH. The treatment of myositis. How to approach resistant disease. Rheum Dis Clin North Am 1995;21:179-202.
2. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill: 1994:1355-83.
3. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994;15:269-74.
4. Whitaker JN, Engle WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med 1972;286:333-9.
5. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1992;89:2970-4.
6. Boldt DH, Von Hoff DD, Kuhn JG, Hersh M. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate (NSC 12887), a new purine antimetabolite. Cancer Res 1984;44:4661-6.
7. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991;9:175-88.
8. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994;120:784-91.
9. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2463-74.
10. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladaribine. Proc Natl Acad Sci USA 1996;93:1716-20.
11. Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladaribine. Semin Hematol 1996;33 Suppl 1:45-52.
12. Davis JC, Austin HA, Boumpas D, et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998;41:335-43.
13. Fessler BJ, Yarboro C, Klippel JH, Hama N, Wilder RL, Boumpas D. A pilot study of fludarabine in refractory rheumatoid arthritis [abstract]. Arthritis Rheum 1995;38 Suppl:S282.
14. Inflammatory myopathy - do we have adequate measures of the treatment response? [editorial]. J Rheumatol 1993;20:1105-7.
15. Bohan A, Peter JB. Polymyositis and dermatomyositis I,II. N Eng J Med 1975;292:344-7:403-7.
16. Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz PH. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991;18:1693-700.
17. Paulus HE. Protocol development for combination therapy with disease-modifying antirheumatic drugs. Semin Arthritis Rheum 1993;23:19-25.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index in lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
19. Hassell AB, Davis MJ, Fowler PD, et al. The relationship between serial measures of disease activity and outcome in rheumatoid arthritis. Q J Med 1993;86:601-7.
20. Rider LG, Feldman BM, Perez MD, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent and patient global assessments. Arthritis Rheum 1997;40:1976-83.
21. Miller F. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20:811-26.
22. Bartlett ML, Ginn L, Beitz L, Villalba ML, Plotz P, Bacharach SL. Quantitative assessment of myositis in thigh muscles using magnetic resonance imaging. Magn Reson Imaging 1999;17:183-91.
23. Kroll M, Otis J, Kagen L. Serum enzyme, myoglobin and muscle strength relationships in polymyositis and dermatomyositis. J Rheumatol 1986;13:349-55.
24. Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am 1992;18:455-82.
25. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia 1993;7:378-83.
26. Wolf RE, Baethge BA. Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 1990;33:1007-114.
27. Miller FW, Love LA, Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol 1990;81:373-89.
28. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Eng J Med 1992;326:1380-4.
29. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996;39:1773-80.
30. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995;49:135-42.
31. Carrera CJ, Terai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest 1990;86:1480-8.
32. Terai C, Wasson DB, Carrera CJ, Carson D. Dependence of cell survival on DNA repair in human mononuclear phagocytes. J Immunol 1991;147:4302-6.
33. Kendall FP. Key to muscle grading. In: Kendall FP, McCreary EK, Provance PG, editors. Muscles, testing and function. Baltimore: Williams & Wilkens; 1993:188-92.
34. Convery FR, Minteer MA, Amiel D, Connett KL. Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 1977;58:494-9.
35. Hicks J, Miller F, Thornton B, et al. Correlation of a functional assessment tool for idiopathic inflammatory myopathy with creatine phosphokinase, manual muscle testing, and aldolase values [abstract]. Arthritis Rheurn 1991;34 Suppl:R31.
36. Sonies BC, Parent LJ, Morrish K, Baum BJ. Durational aspects of the oral-pharyngeal phase of swallow in normal adults. Dysphagia 1988;3:1-10.
37. Sonies BC. Ultrasound imaging and swallowing. In: Jones B, Donner MW, editors. Normal and abnormal swallowing: imaging in diagnosis and therapy. New York: Springer Verlag; 1991:109-18.
38. Logemann JA. Manual for the videofluorographic study of swallowing. Austin: Pro-Ed; 1993.